Retatrutide and tirzepatide are investigated for their effects on metabolic signalling, but they are not interchangeable. Their receptor targets, clinical evidence and regulatory status differ. This research-focused comparison explains the distinctions without suggesting either compound is appropriate for self-treatment.
At a glance
| Feature | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor activity | GLP-1, GIP and glucagon receptor agonism | GLP-1 and GIP receptor agonism |
| Common description | Triple agonist | Dual agonist |
| Evidence | Investigational clinical trial data | Large clinical trial programme and approved medicines in multiple markets |
| Regulatory position | Investigational; not an approved medicine | Approval and indications vary by country and product |
How do they differ?
Both compounds act on GLP-1 and GIP pathways. Retatrutide additionally activates the glucagon receptor, which is being studied for its role in energy metabolism. An additional receptor target does not, by itself, establish better results or safety for an individual.
What does the research show?
Published phase 2 research on retatrutide reported substantial weight changes in study participants, while tirzepatide has been evaluated across multiple large clinical programmes. Comparing percentages across different trials can be misleading because participants, doses, study duration and methods differ. Direct comparative evidence is needed to make reliable head-to-head claims.
For primary sources, see the retatrutide phase 2 trial and the SURMOUNT-1 tirzepatide trial.
Safety and research limitations
Clinical studies have reported gastrointestinal adverse effects and other safety findings. Risks cannot be inferred from receptor count alone. Retatrutide remains investigational, and unapproved products sold online may not have the quality controls of regulated medicines. This article is informational and is not dosing, treatment or purchasing advice.
Further reading on Thai Peptides
Explore our separate research guides: Retatrutide in Thailand and Tirzepatide in Thailand.
Frequently asked questions
Is retatrutide the same as tirzepatide?
No. Retatrutide is a triple receptor agonist under investigation; tirzepatide is a dual receptor agonist used in approved medicines in certain markets.
Does a triple agonist always work better?
No. Receptor activity alone cannot establish comparative clinical outcomes, and separate trials are not a substitute for direct comparison.
Is retatrutide approved in Thailand?
Retatrutide is investigational, not an approved medicine. For current Thai product authorisation information, consult the Thai FDA.
Can research results predict individual outcomes?
No. Clinical trial averages do not predict an individual response, and trial conditions differ from unregulated products.